https://go.evvnt.com/956949-0?pid=5248 Wyndham Boston Beacon Hill
5 Blossom Street
Boston, Massachusetts 02114
Lectures & Conferences
Since 2019, venture capitalists have been predicting a "golden era of neuroscience products" and successes of "radical new breakthrough therapies" in the notoriously challenging space.
Now, three years on, 2022 is hosting the neuroscience renaissance and pharma is doubling down to understand the neuropathological and neuroprotective role of neuroinflammation as the most promising opportunity to bring more targeted, precise and transformative therapies to neurodegenerative and neuropsychiatric diseases.
The 4th Neuroimmunology Drug Development Summit is the timely, industry-definitive forum providing actionable insights to target neuroimmunological mechanisms and advance drug development addressing neuroinflammation.
Download the full event guide here to view the full speaking faculty including Alector, Biogen, Lundbeck, Eisai and Elixiron Therapeutics.
Bringing together department and pipeline Heads across biopharma drug development, join over 100 colleagues to discuss the role of astrocytes, oligodendrocytes and peripheral immune cells; biomarker combinations to diagnose, stratify and design more successful clinical trials; and progress and potential of iPSC-derived organoids for more robust and translatable drug discovery and development research.
Want more content? With four additional workshops hosting detailed discussion and even more focused scientific insights, attend our workshop day to further your understanding into emerging areas of research expansion for neurological pipelines, including: the relationship with traumatic brain injury (TBI) and neuroinflammation, the gut-brain axis, and targeting genetic risk factors in various neurodegenerative, neuropsychiatric and behavioural impairments.
Industry Pricing - Conference Only: USD 2999.0,
Industry Pricing - Conference + 1 Workshop: USD 3298.0,
Industry Pricing - Conference + 2 Workshops: USD 3597.0,
Industry Pricing - Conference + 3 Workshops: USD 3896.0,
Industry Pricing - Conference + 4 Workshops: USD 4196.0,
Vendor Pricing - Conference Only: USD 3599.0,
Vendor Pricing - Conference + 1 Workshop: USD 3998.0,
Vendor Pricing - Conference + 2 Workshops: USD 4397.0,
Vendor Pricing - Conference + 3 Workshops: USD 4796.0,
Vendor Pricing - Conference + 4 Workshops: USD 5195.0
Speakers: Alejandro Rangel, Applied Neurosciences Department Head, Mexican Council of Neuroscience, Andrea Crotti, Principal Scientist, Takeda Pharmaceutical, Andrew Koemeter-Cox, Associate Director, The Michael J Fox Foundation for Parkinson's Disease, Brenda Moore, Research Assistant Professor, University of Florida, Christopher Barnum, Head of Neuroscience, Inmune Bio, Dimitry Ofengeim, Head of Precision Neurology and Neuroinflammation, Sanofi Genzyme, Dong Seok Kim, Chief Executive Officer, Aevis Bio, Francisco Javier Quintana, Professor of Neurology; Associate Member Ann Romney Centre for Neurologic Diseases Brigham and Women's Hospital; Harvard Medicine School; The Broad Institute, Hung-Kai (Kevin) Chen, Chairman and Chief Executive, Officer Elixiron Immunotherapeutics, Jennifer Barnett, Chief Executive Officer, Monument Therapeutics, Jesse Cedarbaum, Acting Chief Medical Officer, ImmnuoBrain Checkpoint, Johan Luthman, Executive Vice President and Head of R and D, Lundbeck A/S, Johannes Grosse, Senior Director of Drug Discovery, Vir Biotechnology, Julie Huang, Senior Scientist, Biomarker Sciences, Alector, Kuti Baruch, Head of R and D, ImmunoBrain Checkpoint, LuLin Jiang, Staff Scientist, Sanford Burnham Prebys Medical Discovery Institute, Malu Tansey, Professor of Neuroscience and Neurology; Co-Director University of Florida College of Medicine; Centre for Translational Research in Neurodegenerative Disease, Marianthi Papakosta, Head of In Vitro Neuroinflammation Pharmacology, Cell Protection Unit and Neuroscience, Takeda Pharmaceuticals, Mark Treherne, Chairman, Talisman Therapeutics, Michael Mingueneau, Director of Research, Biogen, Mike Nagle, Senior Director, Head of Neurogenomics, Eisai, Nikhil Sharma, Founder and Chief Executive Officer, BioCortex, Olivia Corradin, Assistant Professor of Biology, MIT, Paul Ashton, Chief Executive Officer and President, Inflammasome Therapeutics, Richard Wyse, Director of R and D, The Cure Parkinson's Trust, Stan Chamberlain, Chief Scientific Officer, T3D Therapeutics, Stanley Appel, Co-Director, Houston Methodist Neurological Institute; Advisory Board Chair COYA Therapeutics, Thomas Nieland, Director and Head of Target Validation and Exploratory Biology, Verge Genomics, Yung-Chih (Inge) Cheng, Principal Scientist, Pfizer